Inability to interpret toxic salicylate levels in patients taking aspirin and diflunisal

H. M. Adelman, P. M. Wallach, M. T. Flannery

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Diflunisal, a nonsteroidal antiinflammatory drug, is not metabolized to the free salicylate moiety, but yields serum salicylate levels. We describe 2 patients who unexpectedly had toxic range serum salicylate levels while taking diflunisal and aspirin for rheumatoid arthritis. Diflunisal is measured by standard salicylate assays, a fact not widely appreciated. Serum salicylate levels by these assays cannot be used to determine salicylate toxicity when a patient is taking both aspirin and diflunisal. High pressure liquid chromatography can be used to distinguish true salicylate toxicity from interference with diflunisal.

Original languageEnglish (US)
Pages (from-to)522-523
Number of pages2
JournalJournal of Rheumatology
Volume18
Issue number4
StatePublished - Jan 1 1991

Keywords

  • Diflunisal
  • Misleading salicylate levels
  • Salicylate assays
  • Salicylate toxicity

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Inability to interpret toxic salicylate levels in patients taking aspirin and diflunisal'. Together they form a unique fingerprint.

  • Cite this

    Adelman, H. M., Wallach, P. M., & Flannery, M. T. (1991). Inability to interpret toxic salicylate levels in patients taking aspirin and diflunisal. Journal of Rheumatology, 18(4), 522-523.